OBJECTIVE： To evaluate evidence-based guidelines of current global pediatric idiopathic thrombocytopenic purpura （ITP） drug therapy， and to provide evidence-based reference for pediatric ITP diagnosis and treatment， the formulation of guideline in China. METHODS： Retrieved from PubMed， Embase， National Guideline Clearinghouse， Guidelines International Network， TRIP medical database， CBM， CJFD， VIP and WANFANG DATA， etc.， the evidence-based treatment guideline involving pediatric ITP were included， and methodological quality of the guideline was evaluated by using AGREEⅡtool. The similarities and differences of the guidelines were analyzed and compared. RESULTS： A total of 7 pediatric ITP evidence-based guidelines were included， among which 2 came from US， 2 came from Italy， 2 came from British and another one came from Malaysia. The quality of 7 guidelines were not good， among which 6 guidelines were recommended as grade B and 1 guideline was recommended as grade C； only one GRADE evidence-based guideline was found. The score of included guideline in the field of AGREEⅡwas in descending order as scope and purpose， clarity， rigor of development， stakeholder involvement， applicability， editorial independence. The main recommended drugs of these guidelines were： glucocorticoids， intravenous immunoglobulin， anti-D-immunoglobulin， while some guidelines recommend platelet， rituximab and combined medication. CONCLUSIONS： The quality of evidence-based guidelines of ITP for children is in low level and should be improved. There is no evidence-based guideline of ITP for children in China. It is suggested to develop high quality evidence-based guideline for ITP children in China based on AGREEⅡ items.